Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

  • $297M bought by 75 insiders at 59 companies
  • $342M sold by 51 insiders outside a trading plan
  • $2.6B sold by 246 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past week, each insider's filings added up.

  1. SAFXXCF Global
    EEME Energy SPV I, LLC10% owner
    119M shares at $1.19 Oct 16 +109% to stake
    $142M
  2. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    1,815,552 shares at $34.14 Oct 14–20, 5 filings +1.4% to stake 2 superinvestors bought in Q2
    $62M
  3. PAMPampa Energia
    Marcos Marcelo MindlinDirector
    435,000 shares at $80.78 Oct 15 +6.4% to stake
    $35.1M
  4. PEPPepsiCo
    Robert C PohladDirector
    184,646 shares at $128.28 Oct 14 +74% to stake 3 superinvestors bought in Q2
    $23.7M
  5. DOLEDole PLC
    Pale Fire Capital SE10% owner, +4 joint filers
    648,356 shares at $13.19 Oct 20–22 +6.7% to stake
    $8.6M
  6. APLDApplied Digital
    Jason Gechen ZhangPresident
    300,000 shares at $18.86 Oct 16 +12% to stake 5 superinvestors bought in Q2
    $5.7M
  7. BORRBorr Drilling
    Tor Olav TroimDirector
    500,000 shares at $4.60 Oct 15 +1.3% to stake
    $2.3M
  8. RENTRent the Runway
    Nexus Capital Management LPDirector, +9 joint filers
    632,922 shares at $3.55 Oct 21 +15% to stake
    $2.2M
  9. RENTRent the Runway
    CHS US Investments LLC10% owner, +4 joint filers
    458,245 shares at $3.55 Oct 21 +2% to stake
    $1.6M
  10. FBKFB Financial
    Orrin H Ingram IIDirector
    29,081 shares at $52.88 Oct 20 +31% to stake
    $1.5M

Biggest sales

Past week, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    43,111 shares at $46,654.38 Oct 20 0.5% of stake Planned sale (10b5-1)
    $2B
  2. INSWInternational Seaways
    Famatown Finance Ltd10% owner, +2 joint filers
    1,106,190 shares at $97.01 Apr 30–Oct 8 14% of stake
    $107M
  3. SNOWSnowflake
    Frank SlootmanDirector
    300,000 shares at $316.43 Oct 19 94% of stake Planned sale (10b5-1)
    $94.9M
  4. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    4,893,590 shares at $17.55 Oct 15–19, 2 filings 17% of stake
    $85.9M
  5. TRVTravelers
    Alan D SchnitzerCEO
    88,900 shares at $396.77 Oct 21 23% of stake
    $35.3M
  6. PATHUiPath
    Daniel DinesCEO
    2,500,000 shares at $13.23 Oct 15–16 7.9% of stake Planned sale (10b5-1)
    $33.1M
  7. UTHRUnited Therapeutics
    Martine A RothblattCEO
    47,500 shares at $547.72 Oct 15–21, 5 filings 13% of stake Planned sale (10b5-1)
    $26M
  8. MUMicron Technology
    Scott J DeboerPres. & Chief Tech & Prod Offr
    28,545 shares at $900.00 Oct 16 16% of stake Planned sale (10b5-1)
    $25.7M
  9. NTRANatera
    Matthew RabinowitzChair
    50,000 shares at $402.64 Oct 15 2.3% of stake Planned sale (10b5-1)
    $20.1M
  10. AFLAflac
    Japan Post Holdings Co., Ltd.10% owner
    168,611 shares at $118.29 Oct 14–15, 2 filings 0.3% of stake Planned sale (10b5-1)
    $19.9M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 6 insiders, $1.7M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

    Latest buy Oct 23 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

MLYS insider trades

Every open-market buy and sale in MLYS, one row per filing, newest first

MLYS page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Planned sale
    $1.9M 75,000 shares at $25.46 12% of stake
    Traded Sep 30 Filed Oct 2
    ↗
  2. Brian Taylor Slingsby Director
    MLYSMineralys Therapeutics
    Sale
    $3M 104,320 shares at $28.81 1.3% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  3. Eric Warren Chief Commercial Officer
    MLYSMineralys Therapeutics
    Planned sale
    $209K 7,438 shares at $28.12 16% of stake
    Traded Sep 21 Filed Sep 22
    ↗
  4. Daphne Karydas Director
    MLYSMineralys Therapeutics
    Planned sale
    $86K 3,000 shares at $28.58 33% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  5. Eric Warren Chief Commercial Officer
    MLYSMineralys Therapeutics
    Planned sale
    $193K 7,437 shares at $25.98 16% of stake
    Traded Aug 21 Filed Aug 25
    ↗
  6. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $59K 2,170 shares at $27.09 4.1% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  7. Eric Warren Chief Commercial Officer
    MLYSMineralys Therapeutics
    Planned sale
    $200K 7,438 shares at $26.87 16% of stake
    Traded Jul 21 Filed Jul 23
    ↗
  8. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $11K 416 shares at $26.53 0.8% of stake
    Traded Jul 17 Filed Jul 20
    ↗
  9. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Planned sale
    $291K 10,700 shares at $27.24 1.7% of stake
    Traded Jul 13 Filed Jul 15
    ↗
  10. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $557K 20,407 shares at $27.28 28% of stake
    Traded Jul 13–15 Filed Jul 15
    ↗
  11. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $66K 2,171 shares at $30.30 3.6% of stake
    Traded Jul 9 Filed Jul 10
    ↗
  12. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Planned sale
    $2M 75,000 shares at $26.14 11% of stake
    Traded Jun 30 Filed Jun 30
    ↗
  13. Eric Warren Chief Commercial Officer
    MLYSMineralys Therapeutics
    Planned sale
    $2.7M 104,124 shares at $25.90 73% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  14. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $350K 14,474 shares at $24.19 20% of stake
    Traded Jun 15–17 Filed Jun 17
    ↗
  15. Daphne Karydas Director
    MLYSMineralys Therapeutics
    Planned sale
    $75K 3,000 shares at $25.00 33% of stake
    Traded Jun 17 Filed Jun 17
    ↗
  16. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $206K 8,519 shares at $24.20 12% of stake
    Traded Jun 10–12 Filed Jun 12
    ↗
  17. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $11K 417 shares at $27.55 0.7% of stake
    Traded May 18 Filed May 19
    ↗
  18. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $653K 22,575 shares at $28.91 26% of stake
    Traded May 11–13 Filed May 13
    ↗
  19. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $13K 416 shares at $31.33 0.6% of stake
    Traded Apr 17 Filed Apr 21
    ↗
  20. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $549K 20,406 shares at $26.89 23% of stake
    Traded Apr 13–15 Filed Apr 15
    ↗
  21. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Planned sale
    $422K 15,730 shares at $26.83 2.2% of stake
    Traded Apr 13 Filed Apr 15
    ↗
  22. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $59K 2,170 shares at $27.38 2.8% of stake
    Traded Apr 9 Filed Apr 13
    ↗
  23. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Planned sale
    $2M 75,000 shares at $26.27 9.6% of stake
    Traded Mar 31 Filed Apr 2
    ↗
  24. Daphne Karydas Director
    MLYSMineralys Therapeutics
    Planned sale
    $75K 3,000 shares at $25.00 33% of stake
    Traded Mar 31 Filed Apr 2
    ↗
  25. Ra Capital Management, L.P. Director, +4 joint filers
    MLYSMineralys Therapeutics
    Buy
    $8.8M 369,000 shares at $23.75 +6.8% to stake
    Traded Mar 27–30 Filed Mar 31
    ↗
  26. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $11K 417 shares at $25.65 0.5% of stake
    Traded Mar 17 Filed Mar 17
    ↗
  27. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $543K 20,406 shares at $26.61 21% of stake
    Traded Mar 12–13 Filed Mar 16
    ↗
  28. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $58K 2,171 shares at $26.84 2.6% of stake
    Traded Mar 9 Filed Mar 10
    ↗
  29. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $12K 417 shares at $27.59 0.9% of stake
    Traded Feb 17 Filed Feb 17
    ↗
  30. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $570K 20,404 shares at $27.93 32% of stake
    Traded Feb 12–13 Filed Feb 13
    ↗
  31. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $66K 2,171 shares at $30.21 4.1% of stake
    Traded Feb 9 Filed Feb 11
    ↗
  32. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $13K 416 shares at $32.10 0.8% of stake
    Traded Jan 20 Filed Jan 20
    ↗
  33. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $623K 19,076 shares at $32.66 27% of stake
    Traded Jan 13–14 Filed Jan 15
    ↗
  34. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Planned sale
    $530K 16,236 shares at $32.62 2.5% of stake
    Traded Jan 12 Filed Jan 13
    ↗
  35. Adam Scott Levy CFO
    MLYSMineralys Therapeutics
    Planned sale
    $346K 10,758 shares at $32.14 56% of stake
    Traded Jan 12 Filed Jan 13
    ↗
  36. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $277K 8,518 shares at $32.56 12% of stake
    Traded Jan 9–12 Filed Jan 13
    ↗
  37. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $9.3M 262,752 shares at $35.25 81% of stake
    Traded Jan 2–5 Filed Jan 6
    ↗
  38. Brian Taylor Slingsby Director, +1 joint filer
    MLYSMineralys Therapeutics
    Sale
    $43.4M 1,000,000 shares at $43.35 11% of stake
    Traded Nov 20, 2025 Filed Nov 21, 2025
    ↗
  39. Adam Scott Levy CFO
    MLYSMineralys Therapeutics
    Sale
    $5.4M 119,524 shares at $44.88 86% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  40. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Sale
    $9.1M 200,000 shares at $45.44 24% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  41. Daphne Karydas Director
    MLYSMineralys Therapeutics
    Sale
    $690K 15,000 shares at $45.99 100% of stake
    Traded Nov 13, 2025 Filed Nov 13, 2025
    ↗
  42. Alexander M Gold Director
    MLYSMineralys Therapeutics
    Sale
    $1.6M 34,675 shares at $45.45 100% of stake
    Traded Nov 11–13 Filed Nov 13, 2025
    ↗
  43. Adam Scott Levy CFO
    MLYSMineralys Therapeutics
    Planned sale
    $452K 10,758 shares at $42.01 8.4% of stake
    Traded Oct 13, 2025 Filed Oct 15, 2025
    ↗
  44. Jon Congleton CEO
    MLYSMineralys Therapeutics
    Planned sale
    $644K 15,100 shares at $42.67 1.8% of stake
    Traded Oct 13, 2025 Filed Oct 15, 2025
    ↗
  45. David Malcom Rodman Chief Medical Officer
    MLYSMineralys Therapeutics
    Planned sale
    $446K 10,369 shares at $43.01 13% of stake
    Traded Oct 15, 2025 Filed Oct 15, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.